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The GBAP1 pseudogene acts as a 
ceRNA for the glucocerebrosidase 
gene GBA by sponging miR-22-3p
Letizia Straniero1, Valeria Rimoldi2, Maura Samarani3, Stefano Goldwurm4, Alessio Di Fonzo  5, 
Rejko Krüger6, Michela Deleidi7, Massimo Aureli3, Giulia Soldà  1,2, Stefano Duga  1,2 & Rosanna 
Asselta1,2
Mutations in the GBA gene, encoding lysosomal glucocerebrosidase, represent the major predisposing 
factor for Parkinson’s disease (PD), and modulation of the glucocerebrosidase activity is an emerging 
PD therapy. However, little is known about mechanisms regulating GBA expression. We explored the 
existence of a regulatory network involving GBA, its expressed pseudogene GBAP1, and microRNAs. 
The high level of sequence identity between GBA and GBAP1 makes the pseudogene a promising 
competing-endogenous RNA (ceRNA), functioning as a microRNA sponge. After selecting microRNAs 
potentially targeting both transcripts, we demonstrated that miR-22-3p binds to and down-regulates 
GBA and GBAP1, and decreases their endogenous mRNA levels up to 70%. Moreover, over-expression 
of GBAP1 3′-untranslated region was able to sequester miR-22-3p, thus increasing GBA mRNA and 
glucocerebrosidase levels. The characterization of GBAP1 splicing identified multiple out-of-frame 
isoforms down-regulated by the nonsense-mediated mRNA decay, suggesting that GBAP1 levels and, 
accordingly, its ceRNA effect, are significantly modulated by this degradation process. Using skin-
derived induced pluripotent stem cells of PD patients with GBA mutations and controls, we observed 
a significant GBA up-regulation during dopaminergic differentiation, paralleled by down-regulation of 
miR-22-3p. Our results describe the first microRNA controlling GBA and suggest that the GBAP1 non-
coding RNA functions as a GBA ceRNA.
The glucocerebrosidase gene (GBA) encodes for the enzyme glucocerebrosidase (GCase), which catalyzes the 
hydrolysis of the membrane glucosylceramide (GlcCer) to ceramide and glucose. GCase is mainly a lysosomal 
enzyme and only partly associated with the outer surface of the cell membrane1. GCase deficiency leads to the 
accumulation of the substrate, responsible for the multi-organ clinical manifestations of Gaucher’s disease (MIM 
#606463)2, one of the most common lysosomal storage disorders3. While biallelic mutations in GBA are respon-
sible for Gaucher’s disease, heterozygous GBA variants have been repeatedly associated with susceptibility to 
Parkinson’s Disease (PD)4,5. Importantly, Gaucher’s and PDs have been connected due to the clinical observation 
of parkinsonism and Lewy Bodies (LB) pathology in a fraction of patients with Gaucher’s disease6. Compared 
with the general population, patients with the milder form of Gaucher’s disease (type 1) have a 20-fold increased 
lifetime risk of developing parkinsonism7, whereas the odds ratio for any GBA mutation in PD patients compared 
to controls was greater than 5 in a multi-center analysis including more than 5000 cases and 4000 controls8. 
Several studies confirmed that GBA mutations, in particular the two most common ones (p.N370S and p.L444P), 
are more frequent in PD patients than in healthy controls, demonstrating that genetic lesions in this gene are a 
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common risk factor for the disease9,10. Recently, we proved the strong relationship between GBA mutations and 
PD progression and survival11.
Despite many efforts, the mechanism underlying the relation between GBA mutations and the development 
of PD remains unclear. There are studies supporting a gain-of-function effect of the mutated protein (promot-
ing α-synuclein aggregation), as well as others supporting a loss-of-function mechanism (leading to substrate 
accumulation, and hence affecting α-synuclein processing and clearance)12. Widespread deficiency of GCase 
activity has been demonstrated in the brains of PD patients carrying GBA mutations, but it is also significant that 
PD patients without GBA mutations were shown to exhibit deficiency of GCase in the substantia nigra (SN) as 
well as in blood13,14. Moreover, neurons and brains of PD patients showed accumulation of GlcCer that directly 
influences the abnormal lysosomal storage of α-synuclein oligomers, thus resulting in a further inhibition of 
the GCase activity. These findings suggested that the bi-directional effect of GlcCer and α-synuclein accumula-
tion forms a positive feedback loop that may lead to a self-propagating disease15. Recent data also linked GCase 
impairment to the cell-to-cell propagation of α-synuclein aggregates16. Based on the above-mentioned evidence, 
it is plausible that dysregulated GBA levels could represent a common feature in PD, whereas loss-of-function 
GBA mutations could constitute the specific trigger responsible for PD development in the GBA-associated 
disease.
Dysregulation of GBA expression may, in theory, be due to altered epigenetic, transcriptional, and/or 
post-transcriptional regulatory mechanisms. In particular, RNA-based networks, characterized by interactions 
between a specific mRNA, microRNAs (miRNAs), and competitive endogenous RNAs (ceRNAs), are emerging as 
post-transcriptional regulators of gene expression17. Moreover, accumulating evidence points to deregulation of 
noncoding RNAs as an important and largely unexplored regulatory layer in human neurodegenerative disorders, 
such as PD18,19.
MiRNAs are ~20-nucleotide-long regulatory RNAs that act as post-transcriptional regulators of gene expres-
sion by repressing target mRNAs translation and/or by inducing mRNA degradation. About 2000 miRNAs have 
been experimentally validated in humans and many more have been predicted bioinformatically, making them a 
major class of regulators20. Each miRNA might inhibit the expression of multiple target mRNAs, whose recogni-
tion is based on imperfect complementary binding between miRNAs and their target sites, usually located within 
the 3′ untranslated region (3′UTR)21. Recently ceRNAs were described as a novel category of regulatory RNAs: 
these transcripts compete with mRNAs for miRNAs, acting as molecular “sponges” and thus influencing mRNA 
levels17. Pseudogenes are the best ceRNA candidates, since they have a high-sequence identity with the ancestral 
gene (and, consequently, they could be targets of the same miRNAs), they can be transcribed, but usually they 
have lost the ability to generate a functional protein product22. Interestingly, a highly-homologous (96% sequence 
identity) expressed GBA pseudogene (GBAP1) is located 16 kb downstream of the functional gene23,24. GBAP1 
originated from a recent duplication event that occurred no more than 40 million years ago, prior to the diver-
gence of the Great Apes and Old World monkeys, and also involved the metaxin (MTX) gene25,26.
With the aim to better understand GBA expression regulation at the post-transcriptional level, we explored 
the possible existence of a ceRNA-based network involving GBA and GBAP1. Here, we demonstrated that GBAP1 
may function as a ceRNA to regulate GBA expression by sponging miR-22-3p, thus revealing a novel regulatory 
circuit that can play a role in the pathogenesis of PD.
Results
MiR-22-3p targets GBA and GBAP1. Since there is no information on miRNAs modulating GBA expres-
sion, we searched bioinformatically for miRNAs potentially targeting both GBA and its pseudogene. Predictions 
were performed using eight sources of software; candidate miRNA selection was performed by prioritizing miR-
NAs: i) predicted by at least five algorithms; ii) containing at least 7-nt perfect seed match with GBA and GBAP1 
3′UTRs; iii) known to be expressed in the brain and previously implicated in neurodegenerative diseases. These 
filtering steps allowed the selection of three candidate miRNAs: miR-22-3p, miR-132, and miR-212. For func-
tional validation, we prioritized miR-22-3p and miR-132, since they were expressed at a higher level in both the 
cerebellum and frontal cortex (Supplementary Table 1).
To verify that GBA/GBAP1 can be targets of miR-22-3p and/or miR-132, we cloned both miRNA precursors in 
a suitable expression vector, and over-expressed them in HeLa cells for 24 hours. The results of these experiments 
showed that miR-22-3p over-expression can significantly reduce GBA and GBAP1 endogenous mRNA levels 
(up to 72%; P < 0.0003). Conversely, no GBA modulation was detected after miR-132 over-expression (Fig. 1A).
To confirm these results, the 3′UTRs of GBA and GBAP1 were cloned downstream of the luciferase gene in 
the psiCHECK2 vector. These UTRs differ for only 6 nucleotides, none of them mapping in the predicted binding 
sites for miR-22-3p and miR-132. We cotransfected in HeLa cells each of these reporter plasmids together with 
the vector expressing either the miR-22-3p or miR-132 precursor. The results of transfection experiments sub-
stantially confirmed previous observations, i.e. miR-22-3p was able to target both GBA and GBAP1 UTRs (37% 
and 34% reduction, respectively; P < 0.0001). Conversely, miR-132 did not affect the expression of the reporter 
gene (Fig. 1B), and was hence not further investigated.
To better unravel the functional impact of miR-22-3p on the expression of GBA/GBAP1, we decided to study 
miR-22-3p/GBA/GBAP1 expression profiles in 11 cell lines. Real-time reverse-transcription (RT)-PCRs evi-
denced a ubiquitous expression of GBA in the analyzed lines, with highest levels present in HeLa and glioblastoma 
cells, and lowest levels in HepG2 cells. GBAP1 was present in all cell lines, though at lower levels than GBA (from 
186 to 1.8 times less) (Supplementary Figure 1A). MiR-22-3p showed a nearly ubiquitous expression profile, with 
highest levels in HepG2 and glioblastoma cells, and lowest levels in HEK293 (Supplementary Figure 1B).
Based on these expression profiles, we decided to repeat miR-22-3p over-expression experiments in HEK293 
cells. Results were comparable to those observed in the HeLa cell line, with GBA and GBAP1 endogenous mRNA 
levels significantly decreased, after 24 hours, up to 44% (P < 0.05; Fig. 1C). We then confirmed the effects of 
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Figure 1. MiR-22-3p targets GBA and GBAP1. (A) Endogenous expression levels of GBA and GBAP1 after 
pre-miR-22-3p or pre-miR-132 over-expression in HeLa cells. Cells were collected 24 hours after transfection 
and total RNA extracted. Expression levels, measured by real-time RT-PCRs, are shown as normalized rescaled 
values, setting as 1 the value measured in cell transfected with an empty vector (psiUX, mock). (B) Luciferase 
reporter assays of GBA or the GBAP1 3′UTR after pre-miR-22-3p or pre-miR-132 over-expression in HeLa 
cells. 48 hours after transfection, cells were collected and protein lysates prepared for reporter assays. Renilla 
luciferase activity was normalized against the firefly luciferase activity, setting as 1 the value measured in cells 
cotransfected with an empty vector (psiCHECK2, no miRNA overexpression). (C–E) Effect of pre-miR-22-3p 
over-expression in HEK293 cells. Panel C shows the effect on the endogenous GBA and GBAP1 transcripts, 
measured by real-time RT-PCR 24 hours after transfection. Panel D shows the reduction of GBA protein, 
as assessed by Western blot analysis, 48 or 96 hours after transfection. A representative blot (right) and the 
densitometric analysis of three independent experiments (left) are shown. Panel E reports the effect on the 
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miR-22-3p over-expression also at the protein level. Western blot analysis showed a ~20% reduction in the GBA 
protein level at both 48 hours and 96 hours after transfection (Fig. 1D). Measurements of endogenous GCase 
activity demonstrated a 10% and 18% down-regulation after 48 hours and 96 hours of transfection, respectively 
(P = 0.012 and P < 0.003; Fig. 1E).
Finally, the specific binding of miR-22-3p to GBA and GBAP1 3′UTRs was demonstrated by deleting the miR-
22-3p putative miRNA responsive element (ΔMRE) in the reporter constructs containing the relevant UTR, and 
subsequently cotransfecting each mutagenized plasmid together with the miR-22-3p expressing one. In these 
experiments, a luciferase construct containing miR-22-3p antisense sequences (miR-22-3p sensor) was used as a 
positive control27. Our data showed that miR-22-3p responsiveness strictly depends on the presence of the pre-
dicted responsive element in the 3′UTR, since its deletion completely abolishes the miRNA-mediated regulation 
(Fig. 1F). As expected, the level of luciferase activity in the miR-22-3p sensor control dramatically dropped (95% 
reduction).
GBAP1 acts as a ceRNA titrating miR-22-3p and up-regulating GBA. We first verified the coex-
pression of GBA/GBAP1/miR-22-3p in a broad range of samples (20 human tissues as well as 24 different cere-
bral regions). The three transcripts were all ubiquitously expressed (Supplementary Figure 2A,B). In particular, 
GBA showed minimal expression in the skeletal muscle and the highest level in the medial temporal cortex (17 
fold the skeletal muscle). GBAP1 expression levels weakly correlated with those of GBA (Pearson’s correlation 
coefficient of 0.53, P < 0.0013, Supplementary Figure 2C), in agreement with the possible ceRNA role of GBAP1. 
Interestingly, GBAP1 highest expression levels were registered in the brain, where the disproportion between the 
gene and pseudogene levels is one of the lowest (ratio 1:15). Concerning miR-22-3p, although no consistent anti-
correlation was found across the analyzed tissues, the highest miR-22-3p levels were detected in the tissues with 
lowest GBA/GBAP1 expression (Supplementary Figure 2).
These results prompted us to verify if altered levels of GBAP1 could indeed modify the expression of GBA. 
First, as a proof of concept, we over-expressed both the 3′UTR of GBAP1 and the miR-22-3p hairpin in HEK293 
cells. Concurrently, the over-expression experiment was conducted using as sponge the 3′UTR of GBAP1 without 
the miR-22-3p responsive element. We showed that GBAP1 3′UTR over-expression causes a significant increase 
in the levels of endogenous GBA mRNA only in the presence of the miR-22-3p binding site (1.72 fold; P = 0.019; 
Supplementary Figure 3A). We also evaluated the ceRNA effect at the protein level, by measuring the GCase activ-
ity upon miR-22-3p and GBAP1 3′UTR over-expression. Our data confirmed that the GBAP1 3′UTR, containing 
the miR-22-3p binding site, causes a significant increase of GCase activity (1.11 fold; P = 0.013) (Supplementary 
Figure 3B).
Second, considering the high levels of miR-22-3p measured in HepG2 cells (16-fold the levels measured in 
HEK293; Supplementary Figure 1), we over-expressed in this cell line the 3′UTR of GBAP1 alone (with or with-
out the miR-22-3p responsive element) and measured its effect on endogenous GBA. We observed a significant 
increase in the levels of endogenous GBA mRNA, once again only in the presence of the miR-22-3p binding site 
(1.68 fold; P = 0.0016; Fig. 2A). The GBAP1 ceRNA effect through miR-22-3p sponging was confirmed by meas-
uring the expression levels of known miR-22-3p targets, i.e. the SP1 and SIRT1 genes28,29, which both resulted 
in up-regulation of ~1.7 fold (P < 0.015). Conversely, no up-regulation was observed for the CELF1 transcript 
(Fig. 2A), which does not contain any miR-22-3p responsive element. These results were corroborated by the 
measurements of GCase activity and GBA protein levels in HepG2 cells under the same experimental conditions 
(GCase activity: 1.13 fold increase, P = 0.049; GBA protein: 1.40 fold increase, P = 0.020) (Fig. 2B). Finally, a simi-
lar overexpression experiment was repeated using as ceRNA the miR-22-3p sensor, which, in principle, represents 
the “perfect” miRNA sponge. As expected, we observed an up-regulation of all miR-22-3p targets (Supplementary 
Figure 4).
The GBAP1 ceRNA effect could be modulated by the nonsense-mediated mRNA decay (NMD) 
pathway. To better unravel the reciprocal regulation of the couple GBA/GBAP1, we decided to comprehen-
sively study GBA and GBAP1 alternative splicing patterns and the possible regulation of expression of these two 
genes operated by NMD30,31.
To capture the vast majority of all possible splicing events, long-range RT-PCR assays were designed to com-
pletely cover both genes (Fig. 3A). The specific amplification of either GBA or GBAP1 in each assay was assured 
by anchoring one primer to exon 9, in correspondence of the pseudogene-specific 55-bp deletion. RT-PCR assays 
were performed on RNA extracted from HepG2 cells treated or not with the NMD inhibitor cycloheximide. 
This analysis allowed the identification of multiple alternatively-spliced isoforms for GBAP1; conversely, GBA 
did not show any detectable alternative isoform (Fig. 3A). Notably, the heterogeneity of the splicing pattern of 
endogenous GBA-specific GCase activity. In all cases, the value measured in cells cotransfected with an empty 
vector (psiUX, no miRNA over-expression) was set as 1. (F) Luciferase reporter assays of GBA or GBAP1 
3′UTRs, with or without the putative miRNA recognition element (ΔMRE), after miR-22-3p over-expression in 
HEK293 cells. Cells were collected 48 hours after transfection and lysates prepared for reporter assays. Renilla 
luciferase activity was normalized against the firefly luciferase activity, setting as 1 the value measured in cells 
cotransfected with an empty vector (psiCHECK2, no miRNA over-expression). The mir-22-3p sensor27 served 
as positive control. (G) MiR-22-3p/miR-132 fold increase reached in each over-expression experiment (detailed 
below histograms). Error bars represent means +SEM of 3 independent biological replicates, each performed 
at least in triplicate. In all panels, the reference value, set as 1, is indicated by a dotted line. Significance levels of 
t-tests are shown. *P < 0.05; **P < 0.01; ***P < 0.005.
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GBAP1 increased after cycloheximide treatment, suggesting that multiple pseudogene splicing isoforms may be 
modulated by NMD. A tentative reconstruction of the main splicing variants of GBAP1 was performed by a com-
bination of isoform-specific semi-nested RT-PCRs and DNA sequencing, highlighting the presence of multiple 
transcripts containing a premature termination codon (Supplementary Figure 5).
The global effect of NMD degradation on GBA and GBAP1 levels was also investigated by semi-quantitative 
real-time RT-PCR. This analysis showed a significant increase in the expression level of GBAP1 in treated cells 
(4.18 and 3.92 fold in HEK293 and HepG2 cells, P = 0.045 and P = 0.0034, respectively), confirming that this 
pseudogene is down-regulated by NMD (Fig. 3B). Also GBA transcripts were up-regulated upon NMD inhibition 
(2.28 and 2.35 fold in HEK293 and HepG2 cells), a rather unexpected result given the lack of out-of-frame GBA 
isoforms in our preliminary analysis. However, these results suit the hypothesis that GBAP1 levels may influence 
GBA expression through a ceRNA effect. As control, in-frame and out-of-frame PRKCA isoforms, known to be 
insensitive/sensitive to the NMD blockage32, were also analyzed and yielded the expected results (Fig. 3B).
GBA, GBAP1, and miR-22-3p are expressed in induced pluripotent stem cells (iPSCs)-derived 
neuronal cells. To be relevant for the molecular pathogenesis of PD, the GBA/GBAP1/miR-22-3p network 
should work in tissues affected by the disease process, e.g. dopaminergic (DA) neurons. We thus verified the 
expression of GBA, GBAP1, and miR-22-3p in iPSCs and iPSC-derived neuronal cells (after 35 days of differenti-
ation). Semi-quantitative real-time RT-PCR assays were performed on total RNA extracted from iPSCs/neurons 
derived from fibroblasts of six healthy controls and four PD patients (all carrying GBA mutations).
Figure 2. GBAP1 acts as a ceRNA titrating miR-22-3p and up-regulating GBA. (A) Effect of GBAP1 3′UTR 
(with or without the miR-22-3p recognition element, ΔMRE) over-expression on the endogenous transcript 
levels of indicated miR-22-3p targets in HepG2 cells. 24 hours after transfections, cells were collected for 
extracting total RNA for measurements by semi-quantitative real-time RT-PCRs of: i) GBA; ii) SP1 (Sp1 
Transcription Factor; known miR-22-3p target, positive control)28; iii) SIRT1 (Sirtuin 1; known miR-22-3p 
target, positive control)29; and iv) CELF1 (CUGBP, Elav-Like Family Member 1; negative control). The value 
measured in cells transfected with an empty vector (psiCHECK2, mock) was set as 1. (B) Effect of GBAP1 
3′UTR (wild type or ΔMRE) over-expression on GCase activity, measured 96 hours after transfections. (C) 
Effect of GBAP1 3′UTR (wild type or ΔMRE) over-expression on GBA protein level, measured by Western 
blot 96 hours after transfections. A representative blot (right) and the densitometric analysis (left) are shown. 
Error bars represent: means +SEM of 3 (A) or 4 (B) independent biological replicates, each performed at least 
in triplicate; means +SD of 3 independent biological replicates (C, GBAP1 3′UTR). In all panels, the reference 
value, set as 1, is indicated by a dotted line. Significance levels of t-tests are shown. *P < 0.05; **P < 0.01.
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Figure 3. GBAP1 codes for multiple alternatively-spliced isoforms and is modulated by NMD. (A) Analysis of 
GBA and GBAP1 splicing patterns. In the upper part of the panel, a schematic representation of GBA (reference 
sequence: NM_001005741.2) and GBAP1 (reference sequence: NR_002188.2) genes is reported. Exons are 
indicated by boxes, introns by lines. The 55-bp-long sequence characterizing GBA exon 9 is specified by a grey 
rectangle. The scheme is approximately to scale. The overlapping fragments amplified by RT-PCRs to analyze 
the GBA and GBAP1 splicing patterns are indicated by dashed lines and a letter. In the lower part of the panel, 
the electrophoretic analysis (agarose gels 2%) of RT-PCR amplicons is shown. RT-PCRs were performed on 
RNA extracted from HepG2 cells treated (+) or untreated (−) with the NMD inhibitor cycloheximide. On 
the top of each gel, letters indicate the relevant RT-PCR amplicons. (B) Demonstration of the NMD-mediated 
degradation of GBAP1 transcripts. The two panel shows expression levels of GBAP1 and GBA isoforms in 
HEK293 and HepG2 cells, untreated or treated for 8 hours with cycloheximide. Expression levels of endogenous 
GBAP1/GBA isoforms were measured by semi-quantitative real-time RT-PCRs. Results are presented as 
normalized rescaled values, setting as 1 the value of the untreated samples (dotted line). The expression level 
of the Connexin 43 or 32 transcripts, known to be insensitive to NMD, were used in the normalization step. 
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All three players of the regulatory circuit were expressed both in iPSCs and iPSC-derived neurons, respec-
tively. The process of differentiation towards neurons is accompanied by a significant up-regulation of GBA (8 
fold in controls, P = 0.024; 3 fold in patients, P = 0.029) and by a parallel increase in expression levels of GBAP1 
(Fig. 4A and B). In addition, we detected a trend for down-regulation of the GBA transcript in PD patients with 
respect to controls in DA neurons (0.54 fold, P = 0.057). Finally, consistent with the observed up-regulation of 
GBA/GBAP1 during neuronal differentiation, we detected lower expression levels of miR-22-3p in DA neurons 
with respect to their precursors (0.39 fold in controls; 0.18 fold in patients) (Fig. 4C).
Discussion
Despite substantial efforts over the past few years to understand the role of long non-coding RNAs (lncRNAs) 
in health and disease, only some of them have been investigated for their biological function33. One promising, 
although debated, idea assigning to lncRNAs a generalized function is the “ceRNA hypothesis”, based on the 
fact that specific RNAs can limit miRNA activity through sequestration, thus up-regulating the expression of 
miRNA target genes17. In particular, two classes of lncRNAs are increasingly recognized as main ceRNA contrib-
utors, i.e. circular RNAs and pseudogene-derived transcripts34. Indeed, transcribed pseudogenes, mostly deriving 
from duplication events, are considered optimal ceRNA candidates, as they share miRNA-binding sites with the 
ancestral genes17,34. To date, a number of pseudogenes have been experimentally demonstrated to act as ceRNAs, 
including: PTENP1 and KRAS1P22, OCT4-pg435, BRAFP136, and CYP4Z2P37. In this study, we describe a novel 
ceRNA-based network involving GBA, its pseudogene GBAP1, and miR-22-3p (Fig. 5).
The molecular evolution, expression pattern, and mechanisms of transcriptional regulation of GBA have been 
previously investigated38–40, mainly because of its direct link with Gaucher’s disease. On the other hand, the few 
data available on GBA post-transcriptional regulation principally stem from a screening aimed to identify miR-
NAs regulating the GCase activity in p.N370S homozygous Gaucher fibroblasts41. This screening involved 875 
miRNAs and evidenced at least three candidates (miR-127-5p, miR-16-5p, and miR-195-5p), exhibiting a Z-score 
of at least +/−2, with substantial consequences on the GCase activity. However, in all cases, the miRNA effect did 
not seem to be mediated by a direct binding of the miRNA to GBA transcripts; rather, miRNAs acted either on the 
LIMP-2 receptor, which is involved in the trafficking of GCase from the endoplasmic reticulum to the lysosome, 
or on the expression levels of known modifiers of the GCase activity41. Hence, our work identifies miR-22-3p as 
the first miRNA directly targeting GBA. Interestingly, in the publicly-available dataset of Siebert and coworkers41 
miR-22-3p mimic resulted to down-regulate GCase activity (Z-score = −1.5; suggestive P = 0.066), according to 
our results.
Concerning GBAP1, sparse information is available to date, and it is primarily focused on the evolution 
of the GBAP1 locus as an example of a very recently acquired pseudogene23,38. We hence extensively studied 
GBAP1 splicing pattern and expression profile, showing that it is subjected to multiple physiologic in-frame and 
out-of-frame splicing events and that it is broadly expressed, though often at low levels (Supplementary Figure 2). 
More interestingly, we showed that GBAP1 is targeted by NMD, which seems to be the main mechanism regulat-
ing its expression level: blocking NMD, the ratio between GBA and GBAP1 substantially increased (on average 
from 1/100 to 1/68 in HepG2 cells, and from 1/9 to 1/4 in HEK293 cells). Of course, the GBAP1 expression 
control exerted through NMD raises the question about the pseudogene translation, since RNAs should undergo 
a pioneer round of translation, associated with an inspection operated by the NMD machinery, before being 
degraded29. Interestingly, it has been recently reported that many lncRNAs, and even 5′UTRs, are translated, 
and GBAP1 was identified among non-canonical human translated open reading frames42. The remarkable deg-
radation of GBAP1 operated by NMD not only may cause its low abundance, but also results in an increased 
degradation of bound miRNAs, possibly enhancing GBAP1 efficiency as miRNA sponge, as suggested for other 
pseudogenes17.
The relevance of post-transcriptional regulation in determining the low GBAP1 expression is also suggested 
by the observation that GBAP1 proximal and distal promoters show high level of sequence identity with those of 
GBA, and are hence predicted to have similar transcriptional strength. For instance, the presence of two TATA 
boxes and two CAAT boxes in the proximal promoter of GBAP1 exactly recapitulates the architecture of in-cis 
regulatory elements characterizing the GBA proximal promoter23. Moreover, epigenetic marks are not substan-
tially different when comparing the gene and the pseudogene promoters, as inferred from the UCSC Genome 
Browser ENCODE tracks (http://genome.ucsc.edu/; release Feb. 2009, GRCh37/hg19). Indeed, our in-house 
preliminary data, obtained with reporter constructs, show that the activity of GBAP1 promoters does reach the 
transcriptional levels of the corresponding GBA promoters (data not shown).
Our overexpression experiments in different cell lines clearly demonstrated that GBAP1 3′UTR, at supraphys-
iological concentrations, can modulate GBA mRNA levels through a miR-22-3p-mediated regulatory circuit. 
However, these results do not necessarily imply that this ceRNA-based regulation may also work in more phys-
iological conditions. To confirm that GBAP1 can act as a GBA ceRNA without overexpression, we exploited the 
predicted differential sensitivity to NMD of the gene and pseudogene transcripts (see Fig. 3A). Cycloheximide 
treatment allowed us to increase the relative abundance of the endogenous GBAP1 mRNA of around 4 times 
the basal level and was accompanied by a 2-fold increase in GBA transcripts, not directly attributable to NMD, 
and compatible with a ceRNA effect (Fig. 3B). Hence, in specific cells or developmental stages, up-regulation of 
RT-PCRs performed on out-of-frame and in-frame PRKCA isoforms, known to be respectively sensitive and 
insensitive to the NMD blockage32, represent the positive and negative control. Error bars represent means 
+SEM of 3 independent biological replicates, each performed at least in triplicate. Significance levels of t-tests 
are shown. *P < 0.05; **P < 0.01.
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GBAP1, resulting from post-transcriptional or epigenetic regulatory mechanisms, might titrate miRNAs away 
from the GBA protein-coding transcripts, thus providing a physiologic ceRNA effect.
The existence of an RNA-based network controlling GBA expression suggests the intriguing possibility that 
miR-22-3p or GBAP1 dysregulation could also be associated with PD. In this frame, we investigated GBA/GBAP1/
miR-22-3p expression pattern in disease-relevant tissues using in-silico analyses of microarray datasets pub-
licly available through the Gene Expression Omnibus repository (see Supplementary Materials and Methods), 
as well as in-vivo measurements performed on RNA extracted from iPSCs and iPSC-derived neuronal cells of 
Figure 4. GBA, GBP1, and miR-22-3p are expressed in iPS cells and iPSC-derived neurons of PD patients and 
controls. GBA (A), GBAP1 (B), and miR-22-3p (C) expression levels were measured by semi-quantitative real-
time RT-PCRs in up to six iPS and iPSC-derived neuronal cells of cases and controls. Boxplots show expression 
levels according to the disease status; boxes define the interquartile range; the thick line refers to the median. 
Results are presented as normalized rescaled values. Significance level for differences between groups was 
calculated by a Wilcoxon-Mann-Whitney test, and showed only if significant. *P < 0.05.
www.nature.com/scientificreports/
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PD cases and controls. In particular, we retrieved three microarray datasets evaluating differential gene expres-
sion in the SN of post-mortem brains, for a total of 51 cases and 42 controls (Supplementary Table 2). In the 
meta-analysis, we measured a significant down-regulation of both GBA and GBAP1 transcripts in PD patients 
(P < 0.05; Supplementary Figure 6). Notably, we observed the same significant down-regulation for GBA tran-
scripts in iPS-derived DA neurons of PD patients; accordingly, miR-22-3p was slightly, although not significantly, 
up-regulated in cases vs. controls (on average 1.96 fold, P = 0.13; Fig. 4).
A few studies have reported a potential neuroprotective effect of miR-22-3p in rat models of cerebral 
ischemia-reperfusion injury, as well as in Huntington’s and Alzheimer’s disease, through a reduction in inflam-
mation and apoptosis43,44. However, other studies suggested a pro-senescence role of miR-22 in endothelial pro-
genitor cells, in cancer, and in the aging heart and brain28,45–47. While the neuroprotective effects of miR-22 have 
suggested enhancing its expression as a potential therapeutic strategy for the treatment of neurodegenerative con-
ditions, it may well be that miR-22 overexpression represents a pathophysiologic response to protect the cell from 
injury and stress also triggering other non-beneficial effects, like increased aging and reduced GCase activity.
In conclusion, we are aware of the fact that the connection between the RNA-based network and PD patho-
genesis presented here has not been formally proven. However, one can easily imagine a link between the 
down-regulation of the sister transcripts GBA/GBAP1 - or, conversely, the up-regulation of miR-22-3p - and an 
aberrant α-synuclein metabolism, as already theorized12. A confirmed dysregulation of the GBA/GBAP1/miR-
22-3p circuit in PD patients would suggest possible novel therapeutic strategies, based either on the direct control 
of the expression of the miRNA/pseudogene, or on the modulation of the NMD pathway aimed at up-regulating 
GBAP1 levels48.
Methods
Plasmid constructs. MiR-22-3p and miR-132 precursors were inserted into the psiUX expression vector 
(kindly provided by Prof. I. Bozzoni, Università di Roma La Sapienza, Rome, Italy). GBA and GBAP1 3′UTRs 
were directionally cloned downstream of the renilla luciferase gene in the psiCHECK2 reporter plasmid 
(Promega, Madison, USA). All constructs were produced by PCR amplifying the relevant genomic region from 
the DNA of a healthy subject using an appropriate PCR primer couple (Supplementary Table 3), and subsequently 
by cutting the amplified products with the proper restriction enzyme. Restricted products were ligated into the 
relevant plasmid.
Figure 5. Schematic representation of the effect of modulating the GBA/GBAP1/miR-22-3p RNA-based 
network on endogenous GBAP1 and GBA levels. Schematic representation of the ceRNA network involving 
GBA (blue transcripts) and GBAP1 (orange transcripts), harboring the same MRE sites (green and violet ovals). 
The green MRE sites bind to miR-22-3p (in green), whereas violet ones bind to other not-specified miRNAs. 
The experimental modulation of the proposed ceRNA network impacts on both coregulated transcripts. In 
particular, over-expression of miR-22-3p (left part of the figure) determines the down-regulation of both 
GBA and GBAP1 transcripts. Conversely, over-expression of GBAP1 (e.g., by inhibiting the NMD pathway, as 
experimentally verified in the present study; right part of the figure) will increase the cellular concentrations 
of miR-22-3p MREs, thus resulting in the de-repression of GBA. In the scheme, transcripts destined to 
degradation are colored in lighter shades.
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The constructs carrying the GBA and GBAP1 3′UTR deleted of the miR-22-3p binding site (ΔMRE) were 
obtained by site-directed mutagenesis, by means of the QuikChange kit (Agilent Technologies, Santa Clara, USA), 
following the manufacturer protocol.
A pGL3-control luciferase construct containing a single perfectly-complementary miR-22-3p antisense 
sequence (miR-22-3p sensor), kindly provided by Dr. Da-Zhi Wang (Children's Hospital Boston and Harvard 
Medical School), was used as a positive control27.
All plasmids were purified using the PureYield™ Plasmid Miniprep System kit (Promega) according to the 
manufacturer’s instructions. All recombinant and mutagenized vectors were verified by conventional Sanger 
sequencing, as described10.
Prediction of GBA/GBAP1-targeting miRNAs. Predictions were performed using publicly-available 
algorithms: microRNA.org49, MicroCosm Targets50, PITA51, as well as the miRWalk2 suite52.
Cell cultures and transfection experiments. HEK293, HepG2, and HeLa cells (kind gift of Prof. D. 
Fornasari and Prof. A. Rollier, University of Milan, Milan, Italy) were cultured according to the standard proce-
dures. All cell lines were routinely tested for mycoplasma contamination.
For miRNA over-expression experiments, cells were cotransfected using 3.5 µg (HeLa) or 875 ng (HEK293) of 
the psiUX plasmid expressing either miR-22-3p or miR-132 precursors.
For the miRNA-target interaction analysis, HEK293 cells were cotransfected using 300 ng of the psiUX plas-
mid expressing miR-22-3p together with 720 ng of the psiCHECK2 plasmid containing the relevant 3′UTR.
For the ceRNA-effect analysis, HEK293 cells were cotransfected using 300 ng of the psiUX plasmid expressing 
miR-22-3p together with 300 ng of the psiCHECK2 plasmid containing the GBAP1 3′UTR. HepG2 cells were 
transfected with 300 ng of the GBAP1 3′UTR only or with 300 ng of the miR-22-3p sensor (as positive “sponge” 
control).
In each experiment, an equal number of cells (2.5 * 105 for HeLa, 3 * 105 for HEK293, 4 * 105 for HepG2) 
were transfected with the Polyplus jetPRIME (EuroClone, Wetherby, UK) in 6-well plates, as described by the 
manufacturer. Depending on the measurement to be performed at the end of experiment, cells were collected 24, 
48, 72, or 96 hours after transfection (detailed in the relevant figure legend), to obtain either total RNA, or cell 
lysates (see below).
RNA samples. Expression profiles of GBA, GBAP1, and miR-22-3p were determined using RNA from: a 
panel of 20 human tissues (First Choice total RNA; Ambion, Austin, USA), a panel of 24 human cerebral regions 
(Clontech Laboratories, Palo Alto, USA), 11 cell lines, iPSCs, and DA neurons differentiated from iPSCs (see 
below).
RNA from cell lines, iPSCs, DA neurons, as well as transfected cells was isolated using the Eurozol kit 
(Euroclone), according to the manufacturer’s protocol. RNA concentration/quality was assessed using the 
Nanodrop ND-1000 (Thermo Fisher Scientific, Waltham, USA).
Semi-quantitative real-time RT-PCR. For the evaluation of expression levels of specific genes, random 
hexamers and the Superscript-III Reverse Transcriptase (Invitrogen, Carlsbad, USA) were used to perform 
first-strand cDNA synthesis starting from 1 µg of RNA extracted from cells, or RNA derived from a panel of 
human tissues. From a total of 20 µL of the RT reaction, 1 µL was used as template for amplifications using the 
FastStart SYBR Green Master Mix (Roche, Basel, Switzerland) on a LightCycler 480 (Roche), following a touch-
down thermal protocol. Expression levels were normalized using HMBS (hydroxymethylbilane synthase gene) 
and ACTB (β-actin) as housekeeping genes. To discriminate between the quasi-identical GBA and GBAP1 genes, 
we took advantage of the 55-bp deletion in exon 9 characterizing GBAP1 as well as of the few nucleotide differ-
ences between GBA and GBAP1 spread along the two genes.
MiR-22-3p and miR-132 levels were measured by real-time RT-PCR by a poly(A) tailing and a universal 
reverse transcription approach, using the miRNA First Strand Synthesis kit (Agilent Technologies) and starting 
from 300 ng of total RNA, according to the manufacturer’s instructions. RT-PCR reactions were performed using 
the universal reverse primer (Agilent Technologies) and miRNA-specific forward primers, as described53. U6 
snRNA was used as housekeeping gene. Real-time reactions were performed as described above.
In all cases, real-time RT-PCR assays were performed at least in triplicate on a LightCycler 480, and expres-
sion levels were analyzed by the GeNorm software54. Correlation between GBA/GBAP1/miR-22-3p expression 
profiles was calculated using the Pearson’s correlation. Pearson’s coefficients <−0.5 and >0.5 are considered as 
anti-correlation and positive correlation, respectively. P values <0.05 were considered as statistically significant.
Primer couples used in RT-PCR assays are listed in Supplementary Table 3.
Luciferase assays. For miRNA-target interaction assays, the activities of firefly/renilla luciferase were meas-
ured in lysates from transfected cells by using the Dual-Luciferase Reporter Assay System (Promega) and the 
Wallac 1420 VICTOR3 V reader (PerkinElmer, Waltham, USA). The values of renilla luciferase were normalized 
against the corresponding values of firefly luciferase.
Western blot analysis. Cells were lysed in water containing protease and phosphatase inhibitors 
(Sigma-Aldrich, Saint Louis, USA) on ice using an ultrasonic homogenizer. Total cell protein content was meas-
ured using the DC Protein Assay (Bio-Rad, Hercules, USA). In total, 40–50 μg of the protein lysate was loaded 
on a 10% polyacrylamide gel and transferred on a PVDF membrane (GE Healthcare, Freiburg, Germany). Blots 
were incubated with primary antibodies overnight at 4 °C on a shaker platform (Anti-GBA ab128879 1:2.500, 
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Abcam, Cambridge, USA; anti-GAPDH G9545 1:7.000, Sigma) and were then probed with anti-rabbit IgG-HRP 
secondary antibody (1:2.000, Cell Signaling, Leiden, The Netherlands) for 1 h at room temperature. Visualization 
was done by using Westar ETA C 2.0 ECL Substrate for Western Blotting (Cyanagen, Bologna, Italy). For quanti-
tative measurements, membranes were acquired using the Uvitec Cambridge technology (Eppendorf, Hamburg, 
Germany). Image analysis was performed with the Uvitec software.
GCase enzymatic activity assays. Cells to be assayed were washed twice with phosphate buffered saline 
(PBS), harvested, and then lysed in water containing complete protease inhibitor cocktails (Roche). Total cell 
protein content was measured using the Micro BCA assay reagent (Pierce, Rockford, USA). Cells lysates were 
transferred to a 96-well microplate and assays were performed in triplicate. Cell-lysate associated GCase activity 
was analyzed using 4-methylumbelliferyl- β-D-glucopyranoside (MUB-Glc; Glycosynth, Warrington, UK), solu-
bilized at a final concentration of 6 mM in McIlvaine Buffer (0.1 M Citrate/0.2 M Phosphate, pH 5.2) containing 
0.1% Triton X-100. As Triton is a selective inhibitor of β-glucosidase2 (GBA2) activity, these conditions allowed 
the specific measurement of GBA-related GCase activity55,56. The reaction mixtures were incubated at 37°C under 
gentle shaking. The fluorescence was recorded after transferring 10 μL of the mixture in the microplate and add-
ing 190 μL of 0.25 M glycine, pH 10.7. The fluorescence was detected by a Wallac 1420 VICTOR3 V reader. Data 
were expressed as pmoles of converted substrate/mg cell proteins × hour.
GBA and GBAP1 splicing pattern and sensitivity to the NMD pathway. Analysis of GBA/GBAP1 
splicing patterns and susceptibility to NMD was undertaken in HepG2 and HEK293 cell lines. Cells were plated 
at a density of 4 * 105 per 6-well dish and, after 72 hours, treated for 8 hours with cycloheximide (100 µg/mL; 
dissolved in dimethyl sulfoxide) or with the vehicle alone. After the treatment, cells were washed with PBS and 
total RNA extracted.
For the analysis of the splicing pattern, a set of gene-specific or pseudogene-specific RT-PCR assays 
(Supplementary Table 3) was designed to catch the vast majority of possible alternative splicing events. 
RT-PCRs were performed as described above. The main amplified products, recovered from the agarose 
gel using the Wizard SV Gel and PCR Clean-Up System kit (Promega), were directly sequenced to confirm 
their identity.
Variations in the expression levels of GBA/GBAP1 upon treatment were quantified by real-time RT-PCR 
assays using as reference an NMD-resistant transcript (i.e., Connexin 43 or Connexin 32 mRNAs, whose coding 
sequences are all contained in a single exon, for HEK293 and HepG2, respectively). The NMD-sensitive and 
insensitive PRKCA transcripts were used as controls32.
Fibroblast-derived iPSCs. IPSC lines derived from skin fibroblasts of six controls and four PD patients 
carrying heterozygous GBA mutations (p.L444P, n = 2; p.N370S, n = 2) were previously described57 and were 
obtained following the protocol of Takahashi and colleagues58. These iPSCs were subjected to neuronal differen-
tiation for 35 days in vitro, according to Kriks and collaborators’ protocol59.
This study has the approval of the local Ethics Committees (Parkinson Institute, ASST “Gaetano Pini-CTO”, 
Milan, Italy; IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; Medical Faculty and the 
University Hospital Tübingen, Tübingen, Germany) and was performed according to the Declaration of Helsinki. 
Signed informed consent was obtained from all participants.
Data availability. The authors declare that the data supporting the findings of this study are available within 
the article and its Supplementary material file or from the corresponding authors on request.
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